Inhibitex is a clinical-stage biopharmaceutical company dedicated to the development of innovative products that can treat or prevent.
Inhibitex is a clinical-stage biopharmaceutical company dedicated to the development of innovative products that can treat or prevent serious infections. They are applying our expertise in the development of a portfolio of high-value, differentiated infectious disease therapies, each of which has the potential to significantly improve existing standards of care. Their pipeline addresses major viral and bacterial infections, including herpes zoster (shingles), HCV, and S. aureus infections.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Feb 11, 2002 | Series Unknown | $20M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
CDP Sofinov | — | Series Unknown |